Pharmacy

Your Article Summary

See Latest Articles

Cost-Effectiveness Analysis of Anticoagulation Strategies in Non-ST-Elevation Acute Coronary Syndromes
Annals of Pharmacotherapy, 04/01/09

Maxwell CB et al. - Bivalirudin is the least costly agent in moderate- to high-risk NSTE-ACS patients managed with an early invasive approach, if its use is consistent with the ACUITY trial. Fondaparinux is the preferred agent in patients undergoing a conservative treatment strategy.

Today in Cardiac/Hypertension...keeping you current

Receive free subspecialty "5-minute updates" via email

Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09

Beta-Adrenergic Antagonists in Hypertension: A Review of the Evidence
Annals of Pharmacotherapy, 11/25/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

 See all of Cardiac/Hypertension

Today in Pharmacoeconomics...keeping you current

Receive free subspecialty "5-minute updates" via email

Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
PharmacoEconomics, 11/24/09

Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09

Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US
Current Medical Research and Opinion, 11/20/09

 See all of Pharmacoeconomics